The choice and design of the model are evaluated and shown to fit the available data and to support active mitigation of known risks (overfitting, performance degradation, security); the product's clinical benefits and risks are well understood and translated into clinically meaningful performance goals for testing, considering the whole intended population and its subgroups and the uncertainty and variability in inputs, outputs and clinical conditions of use.
The graph holds this control, the 0 it maps to, and the evidence behind each claim, over MCP and REST.